Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: A Multinational Retrospective Study

NCT07091942 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT07091942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07091942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: A Multinational Retrospective Study
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Completed
Start date
July 17, 2025
Completion date
October 8, 2026
Enrollment
243 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma